Aratana Therapeutics (PETX) Tops Q3 EPS by 6c

Aratana Therapeutics (NASDAQ: PETX) reported Q3 EPS of ($0.35), $0.06 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $43 thousand versus the consensus estimate of $220 thousand.

For earnings history and earnings-related data on Aratana Therapeutics (PETX) click here.

You May Also Be Interested In

• Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
• Pelthos Therapeutics Inc. (PTHS) Misses Q2 EPS by 611c
• Pyxis Oncology, Inc. (PYXS) Misses Q2 EPS by 4c